Status:

COMPLETED

Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome

Lead Sponsor:

Pfizer

Conditions:

Overactive Bladder

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This Phase 3 trial will investigate the efficacy, tolerability and safety of fesoterodine fumarate (SR) (fesoterodine; SPM 907) in adult male and female subjects with overactive bladder syndrome. The ...

Eligibility Criteria

Inclusion

  • Overactive bladder syndrome

Exclusion

  • Less than 8 micturitions in 24 hours

Key Trial Info

Start Date :

October 1 2003

Trial Type :

INTERVENTIONAL

End Date :

February 1 2005

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00138723

Start Date

October 1 2003

End Date

February 1 2005

Last Update

April 10 2008

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.